Patents by Inventor Ronnie Hanecak

Ronnie Hanecak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiviral oligonucleotides having a conserved G4 core sequence
    Publication number: 20070015723
    Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
    Type: Application
    Filed: May 17, 2006
    Publication date: January 18, 2007
    Inventors: Ronnie Hanecak, Kevin Anderson, C. Bennett, Ming-Yi Chiang, Vickie Brown-Driver, David Ecker, Timothy Vickers, Jacqueline Wyatt
  • Nr1h4 nuclear receptor binding compounds
    Publication number: 20070010562
    Abstract: The present invention relates to compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.
    Type: Application
    Filed: August 13, 2002
    Publication date: January 11, 2007
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hebert, John Kiely, Ingo Kober, Manfred Kogl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • FXR NR1H4 nuclear receptor binding compounds
    Patent number: 7098336
    Abstract: The invention provides compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: August 29, 2006
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hébert, John Kiely, Ingo Kober, Manfred Kögl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • NR1H4 nuclear receptor binding compounds
    Patent number: 7034046
    Abstract: The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: April 25, 2006
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hébert, John Kiely, Ingo Kober, Manfred Kögl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • NR1H4 nuclear receptor binding compounds
    Patent number: 6974830
    Abstract: The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: December 13, 2005
    Assignee: Phenix Pharmaceuticals AG
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hébert, John Kiely, Ingo Kober, Manfred Kögl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • Antisense modulation of interleukin 12 P35 subunit expression
    Publication number: 20050261228
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p35 subunit are provided.
    Type: Application
    Filed: March 23, 2005
    Publication date: November 24, 2005
    Inventors: C. Bennett, Brenda Baker, Susan Freier, Susan Gregory, Ronnie Hanecak, Kevin Anderson, Ming-Yi Chiang, Vickie Brown-Driver, David Ecker, Timothy Vickers, Jacqueline Wyatt, Eric Marcusson, Nicholas Dean, Sanjay Bhanot, Elizabeth Ackermann, Lex Cowsert
  • NR1H4 nuclear receptor binding compounds
    Publication number: 20030187042
    Abstract: The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.
    Type: Application
    Filed: July 1, 2002
    Publication date: October 2, 2003
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hebert, John Kiely, Ingo Kober, Manfred Kogl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • NR1H4 nuclear receptor binding compounds
    Publication number: 20030149087
    Abstract: The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
    Type: Application
    Filed: July 1, 2002
    Publication date: August 7, 2003
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hebert, John Kiely, Ingo Kober, Manfred Kogl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • FXR NR1H4 nuclear receptor binding compounds
    Publication number: 20030130296
    Abstract: The invention provides compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
    Type: Application
    Filed: August 13, 2002
    Publication date: July 10, 2003
    Inventors: Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hebert, John Kiely, Ingo Kober, Manfred Kogl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
  • Methods for synthetic unrandomization of oligomer fragments
    Patent number: 5698391
    Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled oligomers are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: December 16, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie Hanecak, Timothy Vickers, Peter Davis, Susan M. Freier, Yogesh S. Sanghvi, Vickie Brown-Driver